BAM
Blueshift Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-4,284
| Closed | -$494K | – | 464 |
|
|
2024
Q3 | $494K | Buy |
+4,284
| New | +$494K | 0.12% | 196 |
|
|
2024
Q2 | – | Sell |
-2,705
| Closed | -$373K | – | 397 |
|
|
2024
Q1 | $373K | Buy |
+2,705
| New | +$373K | 0.19% | 164 |
|
|
2023
Q3 | – | Sell |
-4,481
| Closed | -$423K | – | 378 |
|
|
2023
Q2 | $423K | Buy |
+4,481
| New | +$423K | 0.16% | 157 |
|
|
2022
Q2 | – | Sell |
-2,654
| Closed | -$249K | – | 903 |
|
|
2022
Q1 | $249K | Sell |
2,654
-1,702
| -39% | -$160K | 0.02% | 674 |
|
|
2021
Q4 | $371K | Buy |
+4,356
| New | +$371K | 0.03% | 571 |
|
|
2021
Q2 | – | Sell |
-2,120
| Closed | -$206K | – | 1082 |
|
|
2021
Q1 | $206K | Buy |
+2,120
| New | +$206K | 0.02% | 770 |
|
|
2019
Q3 | – | Sell |
-2,874
| Closed | -$243K | – | 874 |
|
|
2019
Q2 | $243K | Buy |
+2,874
| New | +$243K | 0.03% | 609 |
|